UNION, N.J., June 14, 2011 /PRNewswire/ -- PLUS Diagnostics, a leading anatomic pathology company, today announced the appointment of Adnan Savera, M.D. to chief medical officer. A nationally recognized pathologist, Dr. Savera, 44, previously served as the company's executive medical director and led its genitourinary (GU) pathology diagnostic services. In his new role, Dr. Savera will provide medical and strategic direction for all of the company's pathology specialties. He also will continue to serve as director of its GU pathology program.
"I am excited to announce Adnan's promotion and his expanded responsibilities. Under his leadership, we have introduced innovative services that have positioned PLUS Diagnostics as a leading reference laboratory in the urology arena, and enhanced our science, technology and growth. Dr. Savera will be instrumental in leading PLUS Diagnostics through our next phase of growth, which is focused on investing in state-of-the-art diagnostic and consultation services across all of our pathology specialties," said David Pauluzzi, chief executive officer, PLUS Diagnostics.
Dr. Savera joined PLUS Diagnostics in 2010, and in less than a year built a high quality GU pathology program. Previously, Dr. Savera served as chief GU pathologist and medical director for a private lab. He also was a senior staff physician at Henry Ford Hospital, where he revamped its GU pathology services to support its globally acclaimed robotic prostate surgery program. Dr. Savera has been recognized by the U.S. Department of Health and Human Services for his contributions to the field of prostate cancer. He is also listed as one of 'America's Top Physicians' by the Consumer Research Council of America.
PLUS Diagnostics has made a series of investments in its services and technologies since partnering with Water Street Healthcare Partners, a strategic private equity firm focused exclusively on healthcare. In the past four years, the company has opened bi-coastal laboratories, extended its services to the gastroenterology and hematology/oncology specialties, and grown its customer base to increase its net revenues more than 500 percent.
Dr. Savera assumes the chief medical officer position from Dr. Mohammad Kamal, who has decided to focus on his interest in gastrointestinal (GI) pathology. Dr. Kamal will continue to work with PLUS Diagnostics as an independent contractor and provider of GI pathology.
"I would like to thank Dr. Kamal for his service to PLUS Diagnostics," said Pauluzzi. "His vision and leadership have contributed greatly to building PLUS Diagnostics into the national leader we are today."
About PLUS Diagnostics
PLUS Diagnostics is a leading national anatomic pathology company that provides a full range of multi-specialty services, including extensive diagnostic procedures and specialist consultations. Accredited by the College of American Pathologists, PLUS Diagnostics has long been recognized for exceptional service and quality. The company currently focuses on a broad base of specialty pathology services, including urology, gastroenterology and hematology/oncology. PLUS Diagnostics is a company of Water Street Healthcare Partners. For more information, visit, www.plusdx.com.
SOURCE PLUS Diagnostics